Table 2.

Multivariate analysis of the influence of day 21 BM composition and chimerism on neutrophil engraftment in patients who had not engrafted by the day the BM was performed^* incorporating the infused viable CD34+ dose/kg of the unit dominant in engraftment^# (n = 36).

Day 21 BM Characteristic Engraftment RR (95% CI) by BM Characteristic (p value)
% Total Myeloid Precursors in Aspirate	% Cellularity in Biopsy	% Total Donor Chimerism
> 50% (n = 9) Reference	≥ 5% (n = 19) Reference	100% (n = 23) Reference
1–50% (n = 12) HR 0.52 (0.19–1.38) (p = 0.189)	1% (n = 8) HR 0.64 (0.34–1.68) (p = 0.366)	90–99% (n = 7) HR 0.69 (0.24–1.98) (p = 0.490)
0% (n = 15) HR 0.43 (0.16–1.15) (p = 0.094)	0% (n = 9) HR 0.29 (0.09–0.87) (p = 0.028)	< 90% (n = 6) HR 0.13 (0.04–0.47) (p = 0.002)

^*In these 36 patients the BM analysis was performed a median of 21 days post-transplant (range 19–26).

^#The infused viable CD34+ cell dose/kg of the dominant unit analyzed as a continuous variable had a HR of 2.09 (0.84–5.16, p = 0.111).

Abbreviations: HR, hazard ratio; CI, confidence interval; BM, bone marrow.